Lumos Pharma Inc

NASDAQ:LUMO   3:37:03 PM EDT
5.08
+0.06 (+1.30%)
Earnings Announcements

Lumos Pharma Reports Q3 loss Of $0.86 Per Share

Published: 11/14/2022 11:31 GMT
Lumos Pharma Inc (LUMO) - Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates.
Ended Quarter on September 30, 2022 With Cash and Cash Equivalents Totaling $73.7 Million.
Qtrly Loss per Share $0.86.
Q3 Earnings per Share View $-1.01 -- Refinitiv Ibes Data (analyst estimates).
Qtrly Revenue $497 Million.
Q3 Revenue View $66670.00 -- Refinitiv Ibes Data (analyst estimates).
Oragrowth210 Trial is 80% Enrolled and Primary Outcome Readout With All 80 Subjects at Six Months Anticipated 2h 2023.
Lumos Pharma - Interim Data for Potentially First Oral Medication for Pghd From Phase 2 Oragrowth210 and Pk/pd Oragrowth212 Trials Met Expectations.
Cash of $73.7 Million at End of Q3 2022 Provides Runway Into Q2 2024.
Revenue is expected to be $0.1 Million
Adjusted EPS is expected to be -$0.94

Next Quarter Revenue Guidance is expected to be $0.1 Million
Next Quarter EPS Guidance is expected to be -$0.93

More details on our Analysts Page.